Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Venetoclax combos in relapsed/refractory myeloma – ORR of 57% (64% in t (11;14), 26% in non-t (11;14) with hi BCL2), PFS 9.4 mos (11.8 for t (11;14) vs. 2.9 months for non); presence of del (17p) or +1q reduced PFS to 7.7 mos.”
Authors: Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, Leif Bergsagel, Linda Baughn, Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar et al.
More posts featuring Robert Orlowski.